VERNON HILLS, Ill.--(BUSINESS WIRE)--Applied NeuroSolutions, Inc. (OTC BB:APNS) (www.appliedneurosolutions.com), a Company focused on the development of an integrated product portfolio for the treatment and diagnosis of Alzheimer’s disease (AD), today reported that a Position Paper, “Research Criteria for the Diagnosis of Alzheimer’s Disease: Revising the NINCDS-ADRDA Criteria”, was recently published on The Lancet’s web site (www.thelancet.com) and in the August edition of Lancet Neurology (2007; 6:734-746) that describes suggested revisions to the criteria for the diagnosis of Alzheimer’s disease, including the use of cerebrospinal fluid (CSF) biomarkers.